<DOC>
	<DOCNO>NCT01293123</DOCNO>
	<brief_summary>The primary aim study determine effect HIV integrase inhibitor , raltegravir , cerebrospinal fluid ( CSF ) . This accomplish collect CSF initiation either raltegravir another antiretroviral , efavirenz , combination two antiretrovirals . Assessments include HIV RNA level ( viral load ) , neuropsychological testing , mood assessment , quality life assessment .</brief_summary>
	<brief_title>Raltegravir Cerebrospinal Fluid Pharmacodynamic Study HIV-Infected Individuals</brief_title>
	<detailed_description>Cognitive disorder continue common complication HIV disease even though potent antiretroviral drug reduce HIV detectable level restore immune function . Concentrations antiretrovirals nervous system fraction concentration blood . As result , HIV continue present nervous system detection blood . A recently approve drug , raltegravir , reach therapeutic concentration cerebrospinal fluid may effective control HIV replication primary target cell brain , macrophages microglia . Based , raltegravir may particularly effective drug treat HIV disease nervous system . The purpose study determine effect raltegravir nervous system measure HIV CSF ( via lumbar puncture , also know spinal tap ) initiation raltegravir-containing antiretroviral therapy . CSF accessible fluid provide window brain process , include HIV replication inflammation . The potency raltegravir estimate calculate change HIV viral load CSF time . These change compare follow initiation efavirenz-containing regimen separate group individual . Two additional drug ( tenofovir disoproxil fumarate , emtricitabine ) combine either raltegravir efavirenz . Neuropsychological performance , mood , sleep quality life assessment also compare . Participants randomly assign either raltegravir- efavirenz-containing therapy .</detailed_description>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<criteria>1 . Men woman age 1865 year ; 2 . Integrase inhibitornaive subject clinical indication initiate RAL supervision HIV care provider ; 3 . Baseline detectable HIV1 RNA level ≥ 5000 copies/mL plasma ≥ 500 copies/mL CSF ; 4 . Absolute Tcell CD4+ subset 200500/mm3 5 . Individual willing undergo serial lumbar puncture outline study evaluation ; 6 . Subject able give inform consent study procedure ( cognitively impair , individual must pass evaluation ensure adequate comprehension consent document procedure ) ; 7 . Susceptibility study drug Monogram Biosciences PhenoSense GT assay . 1 . Contraindication lumbar puncture , current coagulopathy , thrombocytopenia ( platelet 50,000/µL ) , use anticoagulant ; 2 . Cognitive , psychiatric , substance use disorder medical condition would interfere study participation , opinion investigator ; 3 . Major opportunistic infection ( e.g. , pneumonia , tuberculosis ) within 30 day ; 4 . Use prescribed drug know substantial interaction study drug ; 5 . Positive HCV serology ; 6 . HIVassociated dementia/Global Deterioration Scale ≥4 ; 7 . Pregnancy ; 8 . Serum creatinine high 2.0 mg/dL ; 9 . Total bilirubin alanine aspartate transaminases 3 time upper limit normal</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>HIV</keyword>
	<keyword>raltegravir</keyword>
	<keyword>cerebrospinal fluid</keyword>
</DOC>